3 Biotech Companies Insiders Keep Buying

While the markets may be up from their lows in February and near breakeven for the year to date, it hasn't stopped insiders from taking advantage of seeming bargains to bolster their positions. This is even true in industries that have had a rough time of late, such as biotechnology. It is further sign that some see good things ahead. Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. Companies as diverse as struggling retailers J.C. Penney and Sears, regional bank Huntington Bancshares and consumer products maker Newell-Rubbermaid have seen insiders come to the buy window in a big way, but here we focus on three biotech companies with repeat buys.

The chief executive officer recently scooped up a more than 162,000 shares of

in two transactions, at share prices of $7.50 and $8.05. That cost him more than $1.23 million. The stock has lost about 83 percent of its value in the past year. The market cap of this global company focused on developing fertility treatments now is only about $200 million. The share price is down more than 23 percent since the beginning of the year to the close at $7.47 on Wednesday. The Nasdaq was down less than 5 percent in that time.

The chairman continues to buy batches of shares periodically, as he has done for well more than a year. In the past week he added more than 53,000

shares, while the chief technology officer bought 6,000 shares. At between $9.82 and $10.21 per share, those purchases totaled more than $592,000. This Miami-based health care company has a market cap near $5.6 billion, and it recently posted a positive earnings surprise. Note that short interest is more than 20 percent of the total float. Shares closed most recently at $10.23, up less than 2 percent year to date.

A director added almost 507,000 shares to his stake in this biotech company. At between $32.03 and $33.10 per share, the total for the purchases came to about $22.55 million. Note that this same director also

earlier in the month, and his stake is now over 37.4 million shares.

has a $4.4 million market cap. The stock closed Tuesday at $32.52 a share, after rising more than 18 percent from the 52-week low in February. Since the first of the year, however, shares are still down more than 27 percent.

Keep up with all the latest breaking news and trading ideas by following Benzinga on

.